UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jan

    11

    Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

    Jan

    03

    ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive